Felix Sigal, DPM
Foot & Ankle Surgery · Los Angeles, CANPI 1710974522
Payments from drug & device makers
Across 773 payments — averaging $2865.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$611K
- Vertex$413K
- Novo Nordisk AS$401K
- AbbVie$161K
- Smith+Nephew$137K
- AstraZeneca$127K
- plus $365K from 27 others
Across 51 payments — averaging $8756.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Integra Lifesciences Corporation$250K
- Polarityte, Inc.$133K
- TEI Medical Inc.$37K
- Ipsen Innovation$26K
- Smith+Nephew$360
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 79 | $610,664 |
| Vertex | 3 | $412,935 |
| Novo Nordisk AS | 475 | $401,087 |
| AbbVie | 79 | $160,643 |
| Smith+Nephew | 42 | $137,072 |
| AstraZeneca | 4 | $127,495 |
| Astrazeneca UK Limited | 10 | $116,007 |
| Molnlycke Health Care AB | 2 | $106,553 |
| Novartis | 3 | $84,151 |
| Organogenesis Inc. | 10 | $45,146 |
| Endo Pharmaceuticals Inc. | 1 | $8,700 |
| Integra Lifesciences Corporation | 15 | $1,557 |
| Bristol Myers Squibb | 1 | $1,188 |
| Paratek Pharmaceuticals, Inc. | 21 | $437 |
| ETS Wound Care LLC | 2 | $280 |
| Polarityte, Inc. | 2 | $189 |
| Novo Nordisk | 4 | $129 |
| Urgo Medical North America, LLC | 1 | $123 |
| KCI USA, Inc. | 4 | $99 |
| Cardiovascular Systems Inc. | 1 | $77 |
| Ipsen Innovation | 1 | $50 |
| Polynovo North America LLC | 2 | $36 |
| Solventum Corporation | 1 | $34 |
| Acera Surgical, Inc. | 1 | $29 |
| Orthofix Medical, Inc. | 1 | $23 |
| Mimedx Group, Inc. | 1 | $22 |
| Aroa Biosurgery Incorporated | 1 | $20 |
| Osiris Therapeutics Inc. | 1 | $19 |
| Venclose Inc. | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Acell, Inc. | 1 | $13 |
| Angiodynamics, Inc. | 1 | $13 |
| Amniox Medical, Inc. | 1 | $12 |
How this compares
$2,214,840 in reported general payments places this provider in the 95th percentile of 1,126 foot & ankle surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other foot & ankle surgery in Los Angeles
- Eric TanLos Angeles$447K
- Timothy CharltonLos Angeles$125K
- Suzette LeeLos Angeles$86K
- Christopher KiddLos Angeles$60K
- John ZimmermanBakersfield$4.6M
- Eric GizaSacramento$3.7M
- Thomas HarrisPasadena$3M
- Thomas ChangSanta Rosa$2.1M
- Michael CoughlinSan Francisco$1.6M
- Vladimir ZeetserEncino$677K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.